Model drug
A Study of Effect of Different Cellulosic Polymers on Sustained Release Dosage form Eplerenone as Model Drug
... I hereby declare that this thesis work entitled" A STUDY OF EFFECT OF DIFFERENT CELLULOSIC POLYMERS ON SUSTAINED RELEASE DOSAGE FORM- EPLERENONE AS MODEL DRUG" Submitted to The Tamilnadu Dr.M.G.R ...
103
Formulation and Evaluation of Floating Tablets using Nimesulide as a Model Drug
... changing drug to polymer ratio as 1:1, ...to drug ratio increases. The higher rate and extent drug release was observed from the formulations prepared by 1:1 ratio ...of drug release was less ...
6
Enhancement of solubility and dissolution of poorly soluble drug: Ketoprofen as a model drug
... Further, the formulations were developed by replacing distilled water with sodium citrate solutions (1, 3 and 5%), which acts as an efficient salting-out agent for chitosan [20]. Highest drug release was observed ...
9
DEVELOPMENT AND CHARACTERIZATION OF OSMOTIC DRUG DELIVERY SYSTEM OF MODEL DRUG
... no drug-excipients interaction, the kinetic studies revealed that optimized formulation followed zero order drug release kinetics and stability studies revealed that all the formulations were found to be ...
14
“DEVELOPMENT OF DIRECTLY COMPRESSIBLE METFORMIN HYDROCHLORIDE TABLETS” by Gadekar Shrikant*, Kavade Vishal, Kale Vinita, India.
... of model drug improved the powder functionality properties of the of MH drug powder such as flowability, packability and ...of model drug (MH) was poorly compressed by direct ...
5
In Vitro Studies of NIPAAM MAA VP Copolymer Coated Magnetic Nanoparticles for Controlled Anticancer Drug Release*
... For drug-loading and drug release studies, DOX was used as a model drug. In brief, 60 mg of freeze-dried PNIPAAm-MAA-VP, MNPs 5 mg and 12 mg of DOX were dispersed in phosphate buffer solution ...
8
Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity
... targeting drug delivery system comprising dacarbazine (DTIC)-loaded PLA-DR5 mAb nanoparticles (DTIC-NPs-DR5 mAb) was constructed to combine chemotherapy and active specific immunotherapy in an optimal ...the ...
15
FORMULATION DEVELOPMENT OF MODEL FAST DISSOLVING ORAL FILM OF A POORLY SOLUBLE DRUG WITH IMPROVED DRUG LOADING USING MIXED SOLVENCY CONCEPT AND ITS EVALUATION
... (as model drug) with enhanced drug loading, which was achieved by improving drug solubility and reducing the total surface area of oral film using mixed solvency ...
16
Formulation Development and Evaluation of Floating Microsphere of Acyclovir
... antiviral drug acyclovir (ACV) is one of the oldest molecules laying successful market until date, being commercially available in various dosage forms for oral, topical and parenteral ...this drug is ...
6
Human Hair Keratin Microspheres Prepared by the Water-In-Oil Emulsion Solvent Diffusion Method for Hydrophilic Drug Carrier
... studied drug loading efficiency of the HK microspheres by using blue-dextran a model drug and found that the drug loading efficiency as well as releasing profile of blue-dextran were gradually ...
5
FORMULATION DEVELOPMENT AND EVALUATION OF TRANSFEROSOMAL GEL
... Transfersomes are particularly optimized, ultradeformable (ultraflexible) lipid supramolecular aggregates, which are able to penetrate the mammalian skin intact. Transfersome is a type of carrier system which is capable ...
10
sim.7545.pdf
... of drug combinations shared the same ADE risk ...risk model, the same dimensionality of drug combinations either share the baseline risk that doesn’t depend on the dimensionality of combination ...
32
PREPARATION, FORMULATION AND IN VITRO EVALUATION OF SUSTAINED RELEASE ZOLMITRIPTAN TABLETS BY USING NATURAL POLYMERS
... novel drug delivery system or modifying the molecular structure and or physiological parameters inherent in a selected route of ...a drug in a conventional dosage form [except via intravenous infusion at a ...
11
Mathematical models characterising the kinetics and dynamics of topotecan to account for drug resistance mechanisms
... between drug kinetics and the effect of the drug on the cell cycle ...A model developed by Alarcón et ...the model described by Alarcón et ...obtaining model validation or comparison ...
288
Spread of anti malarial drug resistance: Mathematical model with implications for ACT drug policies
... the model data-driven, the parameters for immu- nity functions and malaria infection in the human host (asymptomatic, symptomatic and recrudescent infec- tions) were obtained from clinical, laboratory and epide- ...
12
Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
... In the nomogram, BIL SS values and its corresponding BIL bas values are associated and, in order to predict an ATZ concentration above 0.2 (MEC), two separate measurements of bilirubin are needed (at baseline and at SS), ...
7
Delivery of definable number of drug or growth factor loaded poly(DL lactic acid co glycolic acid) microparticles within human embryonic stem cell derived aggregates
... Induction of osteogenic differentiation involves Runx-2 up-regulation, which is a key transcription factor during osteogenesis [57 – 59]. Runx-2 is believed to be an upstream regulator for Osterix [60] and is also ...
10
A two-dimensional mathematical model of percutaneous drug absorption
... this model describes, this may give some clue to elucidate the mechanism of y-directional diffusion of the drug (for example, the diffusivity in the stratum corneum may be dif- ferent between x- and y- ...
13
Lung targeted receptor occupancy by drug inhalation : an experimental and computational evaluation
... One commonly used strategy to prolong the pulmonary residence time is to develop drugs with a low solubility in order to reduce the dissolution rate. Indeed, a low aqueous solubility has been demonstrated to give a ...
331
Patients’ preferences for attributes related to health care services at hospitals in Amhara Region, northern Ethiopia: a discrete choice experiment
... full drug availability, continuity of care, good nursing communication, partial drug availability, good physician communication, and shorter waiting time for the ...
9